Date: 2015-05-12
Type of information: Nomination
Compound:
Company: Dyax (USA - MA)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details: * On May 12, 2015, Dyax, a biopharmaceutical company focused on the development and commercialization of novel biotherapeutics for unmet medical needs, announced the appointment of Abbie Celniker , Ph.D., to its Board of Directors. Dr. Celniker currently serves as the President and Chief Executive Officer of Eleven Biotherapeutics, where she also serves on its Board of Directors. Prior to joining Eleven Biotherapeutics, she served as the Executive Vice President, Translational Medicine of Alexion Pharmaceuticals, Inc. From 2008 to 2011, Dr. Celniker served as the President and Chief Executive Officer and as a member of the Board of Directors of Taligen Therapeutics, Inc. which was ultimately acquired by Alexion Pharmaceuticals. Previously, Dr. Celniker served as Global Head of Biologics at Novartis AG, Senior Vice President of Research and Development Strategy and Operations at Millennium Pharmaceuticals, Inc. and as Vice President Protein Technologies at the Wyeth Research facilities in Cambridge, Massachusetts . Dr. Celniker has served as Chair of ImaginAb, a privately held biotechnology company and is currently Vice Chair of MassBio, a not for profit trade organization for biotechnology in the Commonwealth of Massachusetts . Dr. Celniker holds a B.A. in Biology from the University of California , San Diego , and a Ph.D. in Molecular Biology from the University of Arizona .
Financial terms:
Latest news:
